Recent attention has been drawn to the roles of JAK inhibitors on improving responses to immune checkpoint inhibitors in cancer immunotherapy.54,55 Building upon established findings that immunosuppressants like Rapamycin and Cyclosporine A can modulate tumor immunogenicity by suppressing inflammatory responses,56–58 we wonder whether JAK1 inhibitor could act on tumor cells and increase their responses to immunotherapy. This evidence concerns the gene JAK1 and cancer.